SWARTZ CREEK, Mich. Diplomat Specialty Pharmacy on Tuesday announced a joint agreement with Southwest Oncology Network to create SWON-Rx, a comprehensive specialty pharmacy support program to help practices manage oral oncology medications.
SWON is a professional limited liability company whose members are physicians and physician practices whose patients routinely require high-cost, specialty pharmaceuticals specifically for treatment of cancer. SWON currently consists of 65 oncology practices throughout the United States, representing approximately 272 oncologists.
"Diplomat will be SWON's oral oncology Rx solution," stated Mark Neville, Diplomat VP sales and marketing. "With the high number of new oral therapeutic options that have been FDA approved over the past few years, Diplomat's Oncology Navigator has dedicated the required resources to help SWON patients and physicians gain access to these needed medications regardless of the changing reimbursement landscape."
Added Mark Colangelo, SWON VP, "SWON selected Diplomat because of their patient centric reputation in the industry, their high level of customer service, and their commitment to helping oncology patients get the medications they need to obtain optimal clinical outcomes. Diplomat has unique expertise and dedicated resources that assist patients in reducing the financial burdens associated with these life-sustaining medications. SWON member practices value the support this provides their patients and their staff."